"Il Pascale è il maggiore IRCCS Oncologico del Mezzogiorno ed è Centro di Riferimento per la rete oncologica nazionale e regionale. L'Istituto persegue finalità di ricerca prevalentemente clinica, e di ricerca applicata nel campo biomedico e in quello dell'organizzazione e gestione dei servizi sanitari, dedicando grande impegno alle problematiche più ampie del paziente oncologico, che vanno dall'assistenza psicologica ai problemi nutrizionali, alla terapia del dolore, alle cure palliative in genere, fino alle fasi più delicate della malattia."

During the past decade, ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 5 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" #1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator, "GOG Foundation" with 2 trials as a collaborator, "Chugai" with 1 trials as a collaborator and "Exelixis" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" are "Ovarian Cancer" (3 trials), "Cervical Cancer" (2 trials), "Carcinoma, Renal Cell" (1 trials), "Carcinoma, Transitional Cell" (1 trials) and "Fallopian Tube Cancer" (1 trials). Many other conditions were trialed in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" in a lesser frequency.

Most popular intervention types in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" are "Drug" (11 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (8 trials), "Bevacizumab" (3 trials), "Paclitaxel" (3 trials), "Placebo" (3 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" are 5 trials for "Female" genders, 4 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".